Oncogenic pathway inhibition such as BRAF and MEK inhibition in melanoma has shown many effects on tumor and immune cells, including increased expression of melanoma differentiation antigens and HLA on melanoma cells, paradoxical activation of the MAPK pathway in T lymphocytes, induction of PD-L1 expression, and inhibition of suppressive cytokines such as IL-10 and VEGF [29]. This evidence concerns the gene MAP2K7 and melanoma.